Effect of dexmedetomidine on tourniquet-induced skeletal muscle injury
Rev. Assoc. Med. Bras. (1992, Impr.)
; 69(2): 228-232, Feb. 2023. graf
Article
en En
|
LILACS-Express
| LILACS
| ID: biblio-1422623
Biblioteca responsable:
BR1.1
ABSTRACT
SUMMARY OBJECTIVE:
The aim of this study was to investigate whether dexmedetomidine could reduce tourniquet-induced skeletal muscle injury.METHODS:
C57BL6 male mice were randomly assigned to sham, ischemia/reperfusion, and dexmedetomidine groups. Mice in the ischemia/reperfusion and dexmedetomidine groups received normal saline solution and dexmedetomidine intraperitoneally, respectively. The sham group underwent the same procedure as the ischemia/reperfusion group, with the exception of tourniquet application. Subsequently, the ultrastructure of the gastrocnemius muscle was observed, and its contractile force was examined. In addition, Toll-like receptor 4 and nuclear factor-κB expression within muscles was detected by Western blot.RESULTS:
Dexmedetomidine alleviated myocyte damage and increased the contractility of skeletal muscles. Moreover, dexmedetomidine significantly inhibited the expression of Toll-like receptor 4/nuclear factor-κB in the gastrocnemius muscle.CONCLUSION:
Taken together, these results demonstrate that dexmedetomidine administration attenuated tourniquet-induced structural and functional impairment of the skeletal muscle, partly through inactivation of the Toll-like receptor 4/nuclear factor-κB pathway.
Texto completo:
1
Índice:
LILACS
Idioma:
En
Revista:
Rev. Assoc. Med. Bras. (1992, Impr.)
Asunto de la revista:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
MEDICINA
Año:
2023
Tipo del documento:
Article